ERYTHEMA INFECTIOSUM (B19 INFECTION)
|
Structure
& Property |
Transmission |
Pathogenesis |
Clinical
findings |
Laboratory
diagnosis |
Treatment |
|
Family: parvovirus Genome: single-strand DNA Size: 18-26nm Icosahedral, nonenveloped particles |
Transmission by inhalations of infected respiratory secretions. Peak incidence of infection is in childhood, during early school years – from 5 to 10 years old. |
Replicates and is shed in upper respiratory tract. Targets human erythroid progenitor cells; cause lysis leading to anemia. |
20% of those infected have no symptoms. 1st phase: viraemic phase. Symptoms occur at the end of first week: - fever, malaise, myalgia, chills, itching. - erythematous rash, most intense on cheek – ‘slapped cheek disease’ 2nd
phase: - mediated by immune complexes. - rash on body and limbs become maculopapular. - mild lymphadenopathy. - arthralgia with swelling and pain in joints, esp. in women. - resembles rubella. Complications: - Aplastic crises in children with chronic hemolytic anemia. - non-immune hydrops fetalis: affect fetus during maternal infection; cause severe fetal infection and death with fall in hemoglobin level. - Immunodeficiency: chronic anemia |
Serology: - ELISA for IgM - IgM appears 4-7 days - IgG appears 7-10 days later, persist for years. Direct demonstration of viral DNA in tissues and blood, by PCR and DNA probe. Cannot be readily grown in cell monolayer. |
No antiviral therapy available. Blood transfusion in transient aplastic crises. Fetal
infection: - conservative management. - high-dose IgG therapy. - intrauterine fetal transfusion. |